<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148356</url>
  </required_header>
  <id_info>
    <org_study_id>640-0047</org_study_id>
    <nct_id>NCT00148356</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries</brief_title>
  <acronym>ZoMaxx™ I</acronym>
  <official_title>A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx
      drug-eluting stent in patients with blockage of native coronary arteries. The study is
      designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that
      has proven superior to bare metal stents and is a recognized standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart disease is the leading cause of death in Europe as a whole, and while mortality rates
      for cardiovascular disease have decreased in most western European countries, due to expanded
      use of prevention strategies and better treatment, coronary heart disease mortality in the
      middle age groups is increasing rapidly in most of the countries in Eastern Europe. The
      number of procedures performed to treat cardiovascular disease in Europe is constantly
      increasing, although different types of procedures are exhibiting different trends.
      Percutaneous coronary interventions (PCI) procedures, for example, totaled 430,000 in the
      European Union (15 countries) and 520,000 in Europe as a whole (33 countries) in 2000, as
      reported by the Euro Heart Survey, and growth is continuing at a rate of more than 20% per
      year. Despite the effectiveness of intracoronary stents in maintaining a larger luminal
      diameter as compared to angioplasty alone, 15 - 35% of in-stent restenosis occurs within 6 to
      9 months after stent placement. While stents can reduce restenosis by blocking vascular
      recoil and remodeling, mechanical intervention alone is incapable of treating the biological
      problem of neointimal hyperplasia. Various approaches have been used to treat in-stent
      restenosis, including balloon angioplasty, repeat stenting, rotational and directional
      atherectomy, laser and local use of radiation at the time of stenting (brachytherapy).
      However, these techniques add complexity to the interventional procedure and have not had
      documented success in preventing restenosis. Drug-eluting stents (DES) using
      antiproliferative agents delivered via a polymer based stent platform have shown significant
      success in the reduction of restenosis in de novo lesions over the traditional bare metal
      stents in randomized clinical trials. Local delivery of the pharmacological agent allows for
      controlled delivery of high drug concentrations to the targeted tissue while maximizing
      systemic drug effects. The ZoMaxx I Trial is a study of the ZoMaxx Drug Eluting Coronary
      Stent System (ZoMaxx DES) to evaluate the potential benefits of the local application of the
      zotarolimus drug in combination with a phosphorylcholine (PC)-coated tri-metal stent.

      ZoMaxx™ Drug-Eluting Stent System is an Investigational device. Limited by Federal (U.S.) law
      to investigational use only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end-point is in-segment late-loss at 9 months (as measured by QCA), defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiography MLD.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion revascularization(TLR)</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events(MACE) defined as Cardiac Death, MI( Q-wave and non Q-wave) or TVR</measure>
    <time_frame>at 30 days, 6,9,12 months and anually through 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZoMaxx™ Drug-Eluting Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ZoMaxx™ Drug-Eluting Coronary Stent System</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include all of the following:

          -  Subject is ≥ 18 years old.

          -  Female of childbearing potential must have a negative pregnancy test within 7 days
             prior to enrollment and utilize reliable birth control for nine (9) months after
             enrollment.

          -  Subject is eligible for percutaneous coronary intervention (PCI) and has a single
             lesion requiring treatment.

          -  Subject is an acceptable candidate for CABG.

          -  Subject has clinical evidence of ischemic heart disease or a positive functional
             study.

          -  Subject has documented stable angina pectoris

        Exclusion Criteria include all of the following:

          -  Evidence of an acute myocardial infarction (AMI) or CK-MB &gt; 2x upper limit of normal
             within 72 hours of the intended treatment (refer to WHO definition).

          -  Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or
             ticlopidine (Ticlid®), heparin, stainless steel, tantalum, contrast agent (that cannot
             be adequately premedicated), paclitaxel, or drugs similar to ABT-578 (i.e. tacrolimus,
             sirolimus, everolimus).

          -  A platelet count &lt; 100 x 109/L or &gt; 700 x 109/L (&lt; 100,000 cells/mm3 or &gt; 700,000
             cells/mm3); a WBC &lt; 3,000 cells/mm3; or a hemoglobin &lt; 10.0 g/dl.

          -  Acute or chronic renal dysfunction (creatinine &gt; 2.0 mg/dl or &gt; 150 µmol/L).

          -  Subject has had any previous or planned brachytherapy in the target vessel.

          -  Target vessel has evidence of thrombus or is excessively tortuous (&gt; 60 degree bend)
             that makes it unsuitable for proper stent delivery and deployment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Chevalier, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Cardiologique du Nord</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Victoria</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Hospital</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middelheim Algemeen Ziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KU Leuven - UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet / University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Århus</city>
        <zip>Aarhus N</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <zip>83190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardilogique du Nord, 32-36, rue des Moulins Gémeaux</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil - CHU</name>
      <address>
        <city>Toulouse, Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Gatien</name>
      <address>
        <city>Tours</city>
        <zip>37042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Johannes Krankenhaus</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Practice and Hospital Prof. Silber</name>
      <address>
        <city>Munich</city>
        <zip>81379</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Siegburg GmbH</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <zip>2790-134</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bodensee</name>
      <address>
        <city>Kreuzlingen</city>
        <zip>8280</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Tour Hospital</name>
      <address>
        <city>Meyrin-Geneva</city>
        <zip>1217</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW36NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; ZoMaxx I Investigators. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv. 2008 Oct;1(5):524-32. doi: 10.1016/j.jcin.2008.08.010.</citation>
    <PMID>19463354</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Abbott Vascular</name_title>
    <organization>Abbott Vascular</organization>
  </responsible_party>
  <keyword>drug eluting stents</keyword>
  <keyword>stents</keyword>
  <keyword>angioplasty</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>total coronary occlusion</keyword>
  <keyword>coronary artery restenosis</keyword>
  <keyword>stent thrombosis</keyword>
  <keyword>vascular disease</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>coronary artery stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

